CYAD
Closed
Celyad Sa
0.524
-0.030 (-5.42%)
Last Update: 20 Jul 2023 16:30:00
Yesterday: 0.554
Day's Range: 0.524 - 0.524
Send
sign up or login to leave a comment!
When Written:
0.9583
Celyad SA is a clinical-stage biopharmaceutical company that is focused on the development of CAR-T cell therapies for the treatment of cancer. The company was founded in 2004 and is headquartered in Mont-Saint-Guibert, Belgium.
Celyad's lead product candidate is CYAD-01, a CAR-T cell therapy that targets the NKG2D receptor on cancer cells. The company is also developing other CAR-T cell therapies that target different receptors, including CYAD-02, which targets the TIM-3 receptor, and CYAD-211, which targets both the NKG2D and PD-L1 receptors.
In addition to its CAR-T cell therapy programs, Celyad is also developing allogeneic CAR-T cell therapies, which use donor cells instead of a patient's own cells, and non-gene edited T cell therapies.
Celyad has partnerships with several companies, including Novartis, Ono Pharmaceutical, and Dartmouth College, to develop its CAR-T cell therapies. The company is publicly traded on the NASDAQ and Euronext Brussels exchanges under the ticker symbol "CYAD."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Celyad's lead product candidate is CYAD-01, a CAR-T cell therapy that targets the NKG2D receptor on cancer cells. The company is also developing other CAR-T cell therapies that target different receptors, including CYAD-02, which targets the TIM-3 receptor, and CYAD-211, which targets both the NKG2D and PD-L1 receptors.
In addition to its CAR-T cell therapy programs, Celyad is also developing allogeneic CAR-T cell therapies, which use donor cells instead of a patient's own cells, and non-gene edited T cell therapies.
Celyad has partnerships with several companies, including Novartis, Ono Pharmaceutical, and Dartmouth College, to develop its CAR-T cell therapies. The company is publicly traded on the NASDAQ and Euronext Brussels exchanges under the ticker symbol "CYAD."
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!